Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab

Background: With no approved long-term prophylaxis (LTP) for the prevention of hereditary angioedema (HAE) attacks in Hong Kong, patients rely on compassionate use programs and drug trials. Moreover, studies regarding the use and efficacy of LTP in Asia are lacking. Objectives: Our aim was to assess...

Full description

Bibliographic Details
Main Authors: Jane C.Y. Wong, MBBS, FHKCP, Valerie Chiang, MBBS, Dorothy L.Y. Lam, MSc, Elaine Lee, MSc, Ki Lam, MBBS, FRCPA, Elaine Y.L. Au, FRCPA, FHKCPath, Philip H. Li, MD, FRCP
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
Asia
Chinese
lanadelumab
garadacimab
hereditary angioedema
Hong Kong
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829323000917

Internet

http://www.sciencedirect.com/science/article/pii/S2772829323000917

Similar Items